Estimating Hypothetically Negotiated Royalty Rates After MedImmune, Inc. v Genentech, Inc. et al
$25.00v14i3: pp. 43-52 Stenan D. Porter Antitrust 2008
Showing all 2 results

v14i3: pp. 43-52 Stenan D. Porter Antitrust 2008

v15i1: pp. 93-104 David Boyd; Thomas R. Ireland Antitrust 2008
Is there an advantage in using time-series to forecast lost earnings?
1 × $25.00
Annuity testimony and the risk of double discounting
1 × $25.00 Subtotal: $50.00